Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...
Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...
Zacks.com on MSN4h
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADCGilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...
Treasurer Tina Gabler congratulated and thanked the Mount Gilead community and residents as the school board authorized ...
Morrow County Food Pantry co-directors Brenda Harden and Teresa Shipman were delighted with the contributions from Mount ...
In October, lenacapavir manufacturer, Gilead, announced a deal that allows six manufacturers to produce generic versions of ...
The stock's fall snapped an eight-day winning streak.
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
Zacks.com on MSN1d
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback